Elevance Health, Inc., the Indianapolis-based managed care and health benefits company, issued a press release on July 15, 2026, reporting its financial results for the second quarter ended June 30, 2026. The announcement was made public through a current report filed with regulators and signed by Chief Governance Officer and Corporate Secretary Kathleen S. Kiefer. The disclosure covers the company's results of operations and financial condition for the period, though the accompanying press release — furnished as Exhibit 99.1 — was not made available within the filing text itself. Investors in the managed care sector will be closely watching the details of the quarterly results as Elevance Health continues to navigate a complex healthcare environment in 2026.

Key Points

  • NYSE: ELV (also tracked by investors under its NASDAQ-listed profile)
  • Elevance Health disclosed financial results for the second quarter ended June 30, 2026, via a press release dated July 15, 2026
  • Specific revenue, earnings, membership, or guidance figures were not included in the body of the current report; full details are contained in Exhibit 99.1
  • Investors and analysts will be focused on operating metrics, medical cost ratios, and any commentary on the managed care sector outlook as disclosed in the accompanying press release

Elevance Health Files Second Quarter 2026 Results Announcement on July 15

Elevance Health, Inc. formally disclosed its second quarter 2026 financial results through a current report filed with regulators on July 15, 2026. The report states that the company issued a press release on that same date, reporting its financial results for the quarter ended June 30, 2026. The disclosure was executed under Item 2.02, which covers Results of Operations and Financial Condition, indicating that the announcement pertains directly to the company's financial performance during the April through June 2026 period.

The report was signed by Kathleen S. Kiefer, identified as Chief Governance Officer and Corporate Secretary of Elevance Health, Inc. The company is incorporated in the state of Indiana and maintains its principal executive offices at 220 Virginia Avenue, Indianapolis, Indiana 46204. Elevance Health's common stock, which carries a par value of $0.01 per share, trades on the New York Stock Exchange under the ticker symbol ELV.

Press Release Furnished as Exhibit 99.1 — Full Financials Contained Therein

The full financial data released by Elevance Health for the second quarter of 2026 is contained within Exhibit 99.1, which is described in the filing as the press release dated July 15, 2026. The body of the current report itself does not reproduce specific financial metrics such as total revenue, net income, earnings per share, medical loss ratio, or membership figures. Investors seeking detailed operational and financial data would need to refer directly to that exhibit.

It is standard practice in the managed care and health insurance industry for companies to furnish quarterly earnings press releases as exhibits to current reports rather than reproducing all financial details within the report body. The filing confirms that the press release has been incorporated into the current report by reference, meaning the two documents together constitute the complete quarterly results announcement submitted to regulators on July 15, 2026. The company did not disclose specific financial figures in the body of this report.

Classification Under Item 2.02 and Its Significance for Investors

Elevance Health's filing is made under Item 2.02 of the applicable reporting rules, which specifically governs disclosures related to Results of Operations and Financial Condition. This classification signals to market participants that the announcement is directly tied to how the company performed financially during the second quarter of 2026, rather than being related to corporate governance actions, asset transactions, or other operational developments.

The filing includes a standard legal note clarifying that information furnished under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. This means the furnished information is not subject to the same liability standards as formally filed documents, a distinction that is common in earnings-related disclosures from public companies. This legal framing does not diminish the operational or financial relevance of the results for investors and analysts tracking Elevance Health's performance.

Elevance Health's Corporate Profile and Market Position in 2026

Elevance Health, Inc. is one of the largest health insurance and managed care companies in the United States. The company operates across commercial, Medicare, and Medicaid health benefit segments and also runs a health services business through its Carelon subsidiary. With operations spanning multiple states and a broad membership base, the company's quarterly results are closely watched as a bellwether for trends across the broader U.S. managed care sector.

The company was previously known as Anthem, Inc. before rebranding to Elevance Health in 2022 to reflect its evolving identity as a health company rather than solely a health insurance carrier. Its headquarters remain in Indianapolis, Indiana, and the business continues to employ a large workforce across its enterprise. The managed care sector has faced considerable scrutiny in 2026 regarding medical cost trends, utilization rates, and the evolving regulatory landscape, making quarterly disclosures from major insurers particularly significant for investors and policymakers alike.

Regulatory Context: What Item 2.02 Filings Communicate to the Market

When a company of Elevance Health's scale files a current report under Item 2.02, it is communicating to the market that material information regarding its financial and operational performance has been released to the public. This type of announcement is typically accompanied by an earnings call or investor conference in which management discusses results and, in some cases, updates full-year guidance. The filing does not itself confirm whether such a call took place or was scheduled in connection with the July 15, 2026 release.

The filing further confirms that no written communications were made pursuant to Rule 425 under the Securities Act, no soliciting materials were submitted under Rule 14a-12, and no pre-commencement communications were filed under Rules 14d-2(b) or 13e-4(c). These check-box confirmations indicate that the July 15 report is a standalone quarterly earnings announcement and is not connected to any pending merger, acquisition, tender offer, or proxy solicitation as of the date of filing.

Signatory Authority and Corporate Governance Disclosure

The current report was signed on behalf of Elevance Health, Inc. by Kathleen S. Kiefer in her capacity as Chief Governance Officer and Corporate Secretary. This is consistent with standard practice, as corporate secretaries or chief governance officers commonly execute regulatory filings on behalf of companies when the filing relates to routine disclosures such as quarterly earnings announcements. The filing does not reference any changes to executive leadership, board composition, or governance structure.

The presence of a named signatory with the title of Chief Governance Officer and Corporate Secretary reflects Elevance Health's internal governance structure and its commitment to ensuring that regulatory submissions are made by duly authorized individuals. The filing was made effective July 15, 2026, with that date also serving as the date of earliest event reported, meaning the press release and the current report were made contemporaneously on the same day.

Exchange Listing and Securities Registration Details

Elevance Health's common stock is registered under Section 12(b) of the Securities Act and trades on the New York Stock Exchange under the symbol ELV with a par value of $0.01 per share. The company's Commission File Number is 001-16751, and its I.R.S. Employer Identification Number is 35-2145715. These identifiers confirm the entity's registration status and provide continuity of reference for investors and financial data providers tracking the company's filings over time.

The company confirmed in the filing that it is not an emerging growth company as defined under applicable securities regulations. This classification means that Elevance Health is subject to the full range of financial reporting requirements applicable to large accelerated filers and has not elected any extended transition periods for compliance with new or revised accounting standards. This is consistent with the company's long-established status as one of the largest publicly traded health insurance companies in the country.

What Is Not Disclosed in the Current Report Body

Given that the full earnings details are contained within the furnished Exhibit 99.1 rather than the current report itself, the report body does not disclose specific revenue, operating income, net income, adjusted earnings per share, total membership enrollment, medical loss ratio, or any forward-looking guidance figures for the remainder of fiscal year 2026. Investors and analysts looking for granular financial data would need to consult the press release exhibit directly. The company did not disclose this figure in the filing for any specific financial metric within the current report text.

It is also notable that the filing contains no mention of special charges, restructuring actions, litigation settlements, or extraordinary items within the report body. Whether any such items appear in the full press release contained in Exhibit 99.1 cannot be determined from the information available within the current report text itself. Investors may be watching to see whether Elevance Health's second quarter 2026 results reflect any material developments in medical cost trends, Medicaid redetermination impacts, or other sector-specific dynamics that have been widely discussed across the managed care industry throughout 2026.

Immediate Market Reaction and Investor Considerations

The immediate share price impact was not clear from available public information. Quarterly earnings announcements from large managed care companies like Elevance Health can generate significant market reactions depending on how results compare to analyst consensus estimates and whether any changes to full-year guidance are communicated. Without access to the specific financial data contained in Exhibit 99.1, it is not possible to characterize the nature of the results disclosed on July 15, 2026.

Investors following Elevance Health may be focused on a range of factors as they analyze the second quarter 2026 results, including the performance of the company's government programs business, trends in commercial membership, the profitability of its Carelon health services segment, and the broader regulatory and reimbursement environment for managed care organizations operating under Medicare Advantage and Medicaid contracts. These are areas that have drawn significant attention across the sector, and Elevance Health's disclosures are among the most closely watched by institutional investors, analysts, and healthcare policy observers.